Search results below include Worst Pills, Best Pills Newsletter Articles where your
selected drug is a secondary subject of discussion.
April 2012
Find out why you should not use four recently approved heart drugs — dronedarone (MULTAQ), prasugrel (EFFIENT), dabigatran (PRADAXA) and rivaroxaban (XARELTO) — for at least seven years.
January 2012
Find out how to prevent emergency hospitalizations from two commonly used drugs, warfarin (COUMADIN) and clopidogrel (PLAVIX). There are approximately 33,000 emergency hospitalizations a year from warfarin alone. This article includes a list of more than 50 drugs that can have harmful interactions with warfarin and/or clopidogrel.
July 2005
Further evidence that Crestor causes uniquely high rates of muscle and kidney damage
March 2005
If you must use a statin drug to control your cholesterol, you should use one that has an FDA health benefit claim in its professional product labeling.
(chart with these statins listed in the article)
December 2004
We are concerned about any new drug but are particularly concerned about the use of ZETIA together with statins.
December 2004
The letter was prompted by a new Public Citizen analysis of adverse drug reaction reports to the FDA. The analysis found that the rate of reports of kidney failure or damage among patients taking Crestor is 75 times higher than in all patients taking all other statin drugs.
November 2004
Vioxx is the ninth prescription drug to be taken off the market in the past seven years that Worst Pills, Best Pills News readers were previously warned DO NOT USE. The average time between warning readers not to use these drugs and their removal from the market was one year and eight months.
March 2004
We have obtained new information about serious post-marketing adverse reactions — rhabdomyolysis and kidney failure — caused by the recently-approved cholesterol-lowering “statin” drug rosuvastatin (Crestor-AstraZeneca) and have also become aware of decisions by major U.S.health insurors not to reimburse for it.
October 2003
You should try the non-pharmacologic interventions listed in the box below before trying antacids, histamine-2 blockers, or, as a last resort, proton pump inhibitors.
If you classify yourself as a person with frequent heartburn, that is heartburn more than two days per week, and the interventions recommended above have failed, you should be under the care of a physician
December 2002
The following editorial, by Health Letter Editor Dr. Sidney Wolfe, appeared in the December issue of Pharmacoepidemiology and Drug Safety. Ultimately, the cost for such notification should be borne by the pharmaceutical company making the dangerous drug. Pharmacists and/or physicians, if the latter have record access, should be reimbursed for doing the company’s work. In addition, the FDA should be given new legislative authority to impose mandatory drug recalls with an enforceable withdrawal schedule governing the level and rapidity of recall and patient notification.
June 2002
A study published in the May 1, 2002 Journal of the American Medical Association (JAMA) has resulted in a major change in the Health Research Group's drug safety policy. The study, in association with physicians from the Harvard Medical School, examined the frequency and timing of the identification of new adverse drug reactions resulting in the addition of a black box warning in the drug's professional product labeling or its outright removal from the market.
Three of the authors have close identification with the Health Research Group: its director, Sidney M. Wolfe, and former HRG staffers Drs. Steffi Woolhandler and David Himmelstein. The other co-authors are affiliated with the Harvard Medical School.
Login
Subscribe